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Smoldering myeloma presenting as progressive
multifocal leukoencephalopathy: a case report
Martina Troppmann1*, Roland Büttner1 2 and Bernd Salzberger1Abstract
Introduction: Progressive multifocal leukoencephalopathy is an opportunistic infection occurring in patients with
severe cellular immunodeficiency. This case highlights the role of cellular immunodeficiency in the reactivation of
John Cunningham virus in a case of an early stage plasmacytoma.
Case presentation: A 76-year-old Caucasian woman presented with progressive left-sided hemiparesis,
accompanied by hypoesthesia, hypoalgesia and neuropsychological symptoms. Magnetic resonance imaging
demonstrated new hyperattenuating lesions in the right thalamus and left-sided subcortically. A polymerase chain
reaction test revealed 4500 copies of John Cunningham virus-deoxyribonucleic acid/ml in cerebrospinal fluid.
Human immunodeficiency virus infection was ruled out. A bone marrow biopsy showed an early stage
immunoglobulin G-kappa plasmacytoma. Cidofovir (5mg/kg) weekly for three weeks was started. A significant
improvement of her neuropsychological symptoms was achieved, but motor system and sensory symptoms
did not change.
Conclusions: This case shows a rapid course of progressive multifocal leukoencephalopathy with severe residual
deficits. In the diagnostic workup of all patients with atypical neurologic symptoms or immunodeficiency,
progressive multifocal leukoencephalopathy should be included as a differential diagnosis.
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Progressive multifocal leukoencephalopathy (PML) is an
opportunistic infection occurring in patients with severe
cellular immunodeficiency. It is caused by reactivation of
the John Cunningham (JC) polyomavirus. The preva-
lence of JC virus infection in the healthy population is
estimated at 66% to 92% [1]. Primary infection usually
does not result in clinical symptoms, but the virus per-
sists in the kidney in a latent state. With immunodefi-
ciency, however, the virus can reactivate, undergo
genetic changes and lead to the clinically apparent
neurologic manifestations of PML. Typically, PML is
found in human immunodeficiency virus (HIV)-infected
patients as an acquired immunodeficiency syndrome
(AIDS)-defining illness, but organ and stem cell trans-
plant patients, patients with hematological malignancies
and patients treated with natalizumab are also at risk.* Correspondence: martina.troppmann@klinik.uni-regensburg.de
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distribution, and reproduction in any mediumLytic infection of the myelin-producing glia cells leads to
a multifocal demyelinization of cerebral white matter.
The clinical manifestations depend on the localization of
the lesions. Common symptoms are motor weakness, es-
pecially hemiparesis, visual deficits such as hemianopsia,
and mental changes from circumscript single cognitive
deficits up to dementia [2].
For the diagnosis of PML a magnetic resonance im-
aging (MRI) scan of the brain and cerebrospinal fluid
examination are necessary. A cerebral MRI has a higher
sensitivity in imaging of PML than cerebral computed
tomography (CT) [3]. On T2-weighted images, MRI typ-
ically shows hyperattenuating lesions without mass effect
[3]. The detection of JC virus (JCV) deoxyribonucleic
acid (DNA) in cerebrospinal fluid by polymerase chain
reaction (PCR) is needed for the diagnosis of PML. In
some cases a biopsy may be necessary to either make a
definite diagnosis or rule out other diseases, such as
toxoplasmosis or lymphoma [4,5].
There is no standard therapy for PML. Improving the
immunological status with highly active anti-retroviralntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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stone in patients with HIV infection.
Therapy with alpha-interferon and cytarabine showed
no clinical efficiency [6,7]. Cidofovir, a nucleotide analog
of deoxycytidine monophosphate, shows in vitro activity
against JCV but cidofovir has not been evaluated in a
prospective randomized trial in patients with PML. Case
series and reports do not demonstrate a clear benefit of
therapy with cidofovir.
This case report demonstrates the occurrence of PML
in a formerly healthy patient including treatment with
cidofovir.
Case presentation
A 76-year-old Caucasian woman from Bavaria, Germany
was admitted to a primary care hospital with acute
paresthesia of the left hand and face. Her clinical exam-
ination revealed a hemiparesis of the left part of the
body, accompanied by hypoesthesia, hypoalgesia and
neuropsychological symptoms. An initial cerebral CT
showed no signs of acute ischemia or bleeding. Subse-
quent cerebral MRI revealed a subcortical lesion in the
right hemisphere, first interpreted as lacunar infarction.
Despite standard treatment for cerebral ischemia, the
hemiparesis was progressive and she was transferred to a
neurology unit. Control MRI scanning took place, and
the T2-weighted analysis showed new hyperattenuating
lesions in the right thalamus and left-sided subcorticalFigure 1 In the initial scan, T2-weighted (A) axial magnetic resonance
(arrows). The diffusion-weighted image (B) shows mild hyperintensity of t
(C) shows no significant enhancement. In the scan obtained three weeks la
the right (arrow). The diffusion-weighted image (E) reveals a marked highe
subcortically (arrowheads). The postgadolinium T1-weighted image (F) now
enhancement of lesions bilaterally (arrowheads).regions. Other lesions located in both periventricular
and subcortical white matter remained unchanged.
Diffusion-weighted imaging now demonstrated abnor-
mal diffusion, especially in the right thalamus. In many
of those older and newer lesions, T1-weighted postgado-
linium images revealed patchy and faint enhancement
which was not found in the first MRI study (Figure 1). A
cerebrospinal fluid examination excluded bacterial men-
ingoencephalitis, Lyme disease, tick-borne encephalitis,
Herpes-simplex-virus 1 and 2 and Creutzfeld-Jacob Dis-
ease. Due to the radiological appearance of the lesion, a
PCR test for JCV-DNA was performed which revealed
4500 copies of JCV-DNA/ml in her cerebrospinal fluid
(CSF) (Table 1). Testing for HIV-infection was repeat-
edly negative.
The differential blood cell count revealed severe rela-
tive lymphocytopenia with only 8% lymphocytes. Serum
immunofixation demonstrated a monoclonal IgG type
kappa with hypogammaglobulinemia. On bone marrow
biopsy a diffuse plasma cell infiltration of 20% was
found. She was then transferred to our hospital. Past
medical history included bronchial asthma, arterial
hypertension, cardiac arrhythmia and allergies to mul-
tiple drugs. Medication consisted of candesartan and
hydrochlorothiazide 8/12.5mg once a day, clopidogrel
75mg once a day, verapamil 120mg once a day, and ipra-
tropium bromide 250μg. She did not have fever, nausea,
emesis or headache.imaging scan demonstrates small foci of disease bilaterally
he lesion on the right (arrow). The postgadolinium T1-weighted image
ter, the T2-weighted image (D) reveals a mild change in the lesion on
r signal intensity as in (B) (arrow) and shows new lesions left-sided
demonstrates marked progression of disease with patchy
Table 1 Cerebrospinal fluid examination
parameter value reference value
cell count 3.3/μl 0.0 to 0.4μl
protein 86mg/dl 15 to 50mg/dl
albumin 51.3mg/dl 13.9 to 24.6mg/dl
glucose 56mg/dl –-
lactate 2.1mmol/L 1.1 to 2.1mmol/L
IgG 10.50mg/dl 0.48 to 5.86mg/dl
polyoma (JCV) DNA-PCR 4500 copies/ml negative
protein 14-3-3 negative negative
FSME (tick-borne
encephalitis) – IgG and – IgM
negative negative
Measles – IgG and – IgM negative negative
Lyme – IgG and – IgM negative negative
Ig immunoglobulin.
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tive, oriented with regard to time, place, person and situ-
ation but had difficulty concentrating. Neurologic
examination confirmed a left-sided hemiparesis, espe-
cially of the lower extremity.
Laboratory tests on admission are presented in
Table 2.
Lymphocyte differentiation was done by fluorescence
activated cell sorter (FACS) analysis. Results are shown
in Table 3.
Further laboratory diagnostics showed a ß2-
microglobulin of 2.92mg/l (0.7 to 1.8) and negative
results for anti-HIV/HIV-antigen, hepatitis B virusTable 2 Laboratory parameters on admission
parameter unit value reference value
sodium mmol/l 137 135 to 150
potassium mmol/l 3.7 3.50 to 5.50
creatinine mg/dl 0.82 0.50 to 0.90
CK U/L 121 26 to 140
LDH U/L 321 + 100 to 247
GOT U/L 46 + <35
GPT U/L 37 + <35
bilirubin mg/dl 0.4 <1.00
protein g/L 61.5 - 64 to 83
albumin g/L 34.4 - 37.0 to 53.0
CRP mg/L 46.22 + <5.00
leucocytes /nl 5.13 4.80 to 10.80
erythrocytes /pl 4.73 3.80 to 6.10
hemoglobin g/dl 15.1 11.7 to 15.7
thrombocytes /nl 251 130 to 440
CK creatine kinase, CRP C-reactive protein, GOT serum glutamic oxaloacetic
transaminase otherwise known as aspartate transaminase (AST) or aspartate
aminotransferase (ASAT), GPT serum glutamic pyruvic transaminase otherwise
known as alanine transaminase or alanine aminotransferase (ALAT), LDH
lactate dehydrogenase.surface (HBs)-antigen, anti-hepatitis B virus core (HBc)
and anti-hepatitis C virus (HCV).
Skeletal involvement of plasmacytoma was ruled out
by a radiographic series involving cervical, thoracic and
lumbar spine, hips, femur, knees, upper arm and neigh-
boring joints.
A diagnosis of PML secondary to immundeficiency
was made. With the results of the bone marrow biopsy
and serum immunofixation a diagnosis of an early stage
plasmacytoma or smoldering myeloma was made. No
other cause of immunodeficiency was found. Antineo-
plastic chemotherapy was not started immediately as
lymphopenia might be enhanced and JCV-infection
might be promoted at this time.
For PML we started cidofovir 5mg/kg intravenously
weekly for three weeks. After the second administration
of cidofovir a slight cognitive improvement was noticed.
She started to be more active and communication
improved. However, the hemiparesis did not regress. She
was sent to a neurologic rehabilitation department two
weeks after admission, where a third dose of cidofovir
was given. The cognitive deficits recovered further.
Short- and long-term memory, communication and
orientation recovered fully. Hemiparesis of the left part
of the body and incontinence for urine and stool per-
sisted. She was not able to sit up, walk or eat on her
own. No other manifestations of plasmacytoma devel-
oped during her follow-up. An antineoplastic chemo-
therapy was not initiated because the neurologic
sequelae due to PML were considered not to be revers-
ible and no other indication for chemotherapy was
present. Nine months after diagnosis of PML she is in a
stable, but severely impaired physical condition.Discussion
This patient not only had lymphocytopenia but more
specifically a dramatic low CD4- (T-helper) cell count of
72/μl. In analogy to HIV-infection the risk of anTable 3 FACS-Analysis of lymphocyte subsets 29 April
2008
parameter unit value reference value
leucocytes /nl 4.75 - 4.80 to 10.80
lymphocytes /nl 0.47 - 1.0 to 2.8
T- lymphocytes % lymphos 27 - 55 to 83
B- lymphocytes % lymphos 17 6 to 19
NK-cells % lymphos 47 + 7 to 31
CD4+ cells % lymphos 15 - 28 to 57
CD8+ cells % lymphos 10 10 to 39
T- helper cells /μl 72 - 300 to 1400
T- suppressor cells /μl 48 - 200 to 900
FACS fluorescence activated cell sorter.
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of PML in patients with hematologic malignancies with
low CD4-cell counts has been reported before. For in-
stance, Re et al. reported a case of PML in a patient with
hematological malignancy and a low CD4 cell count.
One year after autologous bone marrow transplantation
for therapy of a mantle cell lymphoma the patient devel-
oped neurological symptoms [8].
The differential diagnosis between cerebral ischemia
and PML, as demonstrated in this case, can be difficult.
Multiple neurologic complications and progressive dis-
ease should raise a suspicion and lead to further diag-
nostic procedures. MRI is the most sensitive imaging
procedure in patients with PML. Definite diagnostic pro-
cedures are the detection of JC-DNA in cerebrospinal
fluid or brain biopsy.
Our patient demonstrated a modest clinical response
to antiviral therapy. A near complete recovery of neuro-
psychological symptoms could be achieved but her
hemiparesis and the incontinence remained. Nine
months after the diagnosis of PML she is still alive with
stable neurological symptoms. Because of the clinical
improvement follow up cerebrospinal fluid examinations
and MRI scans were not performed.
Early stage plasmacytoma is the most likely cause of
severe lymphocytopenia and immunodeficiency. Lym-
phocytopenia in this patient may have been further
enhanced by the use of glucocorticoids for severe bron-
chial asthma just before the occurence of PML symp-
toms. An exact dose and timing of application could not
be reconstructed.Conclusions
This case of a rapid progressive PML highlights the role
of cellular immunodeficiency in the reactivation of JC-
virus and the occurrence of PML. The clinical course
may have been positively influenced by the use of cido-
fovir, although restitution of motor system functions
could not be achieved. PML should be included as a dif-
ferential diagnosis in all patients with cellular immuno-
deficiencies and rapid neurological deterioration. MRI
scans may reveal typical or atypical findings and JC-virus
can be detected by cerebrospinal fluid analysis or in
brain biopsies.Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
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